Janssen Enters License Agreement with Protagonist Therapeutics
The company entered a collaboration with Protagonist to develop, manufacture, and commercialize PTG-200.
On May 30, 2017 Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson, announced that it has entered into a worldwide exclusive license and collaboration agreement with Protagonist Therapeutics, Inc. to develop, manufacture, and commercialize PTG-200, an oral interleukin-23 receptor (IL-23R) antagonist drug candidate in development for the treatment of Crohn’s disease and ulcerative colitis.
Under the terms of the agreement, Protagonist will receive a $50 million upfront payment and potentially up to an additional $940 million in development and sales milestones. If PTG-200 is commercialized, Protagonist would be eligible to receive royalties on net sales and will also have the option to co-detail in the US.
PTG-200 is currently in Investigational New Drug (IND) enabling studies, and the initiation of a Phase I clinical trial is planned in 2017.The transaction is expected to close in the third quarter of 2017.
Source: Janssen, Protagonist
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
August 5th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.
